Eurofins CDMO

Planegg, DE · San Diego, CA
Biologics Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-29
81.6
Signal Score
✓ FDA Inspections (4) ○ Clinical Trials ○ SEC Filings ✓ Press (8) ○ EMA GMP ○ MHRA GMP

Quick Facts: Eurofins CDMO

Signal Score
81.6/100 (as of 2026-04-29)
Quality Compliance
100.0/100 — Bonus: 3 consecutive NAI inspections
Headquarters
Planegg, DE · San Diego, CA
Modalities
Biologics, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Eurofins CDMO

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
Bonus: 3 consecutive NAI inspections
Source: FDA Data Dashboard
Bonus: 3 consecutive NAI inspections
FDA Inspections4 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-12-12)
Bonus: 3 consecutive NAI inspections
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 68.0
Parent company: Eurofins Scientific
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Eurofins Scientific
Financial assessment: 68.0/100
Capacity 63.0
2 manufacturing sites
Sites: Planegg, DE, San Diego, CA
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
Recent Press8 articles
2 manufacturing sites

FDA Inspection History

2025-12
2025-06
2025-03
2024-07
NAI VAI OAI
Date Site Type Observations Classification
2025-12-12 Philadelphia, Pennsylvania Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2025-06-27 Winston Salem, North Carolina Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2025-03-26 Irwindale, California Human Cellular, Tissue, and Gene Therapies No No Action Indicated (NAI)
2024-07-19 Centennial, Colorado Human Cellular, Tissue, and Gene Therapies No Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved May 20, 2026

Recent News 8 articles

regulatory 2026-04-21
Dr. Kirithivasan Venkatesan Appointed as Senior Director – Process R&D at Eurofins CDMO India - hrtoday.in
Dr. Kirithivasan Venkatesan Appointed as Senior Director – Process R&D at Eurofins CDMO India  hrtoday.in
Source →
general 2026-04-17
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - BioSpace
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing  BioSpace
Source →
general 2026-04-16
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Business Wire
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing  Business Wire
Source →
general 2026-04-16
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Bluefield Daily Telegraph
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing  Bluefield Daily Telegraph
Source →
general 2026-04-16
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing - Yahoo Finance
Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing  Yahoo Finance
Source →
general 2026-03-10
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - The Manila Times
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study  The Manila Times
Source →
general 2026-03-10
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ... - Caledonian Record
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ...  Caledonian Record
Source →
general 2026-03-10
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study  Bitget
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
Signal Score: 81.8
mRNA, Biologics, Cell Therapy
Syngene International
Bangalore, IN
Signal Score: 79.7
Biologics, Cell Therapy
Singota Solutions
Bloomington, IN
Signal Score: 59.0
Cell Therapy, Biologics
Roche / Genentech (Internal Manufacturing & CustomBiotech)
Basel, Switzerland
Biologics, mAb, Cell Therapy, Gene Therapy (AAV), Oligonucleotide, mRNA, Small Molecule
Altruist Biologics
Suzhou, China
Biologics, mAb, Bispecific/Multispecific Antibodies, Fusion Proteins, Recombinant Proteins, ADC, Cell Therapy, Gene Therapy